Molecular basis of Alzheimer's disease

American Journal of Health-System Pharmacy

Volumn 53, Issue 13, 1996, Pages 1545-1557

  Gooch, Michael D ^a,b   Stennett, Douglass J ^b,c  

^a PITT COUNTY MEMORIAL HOSPITAL   (United States)

^b OREGON STATE UNIVERSITY   (United States)

^c Department of Pharmacy Practice   (United States)

Author keywords

Alzheimer's disease; Anti inflammatory agents; Antioxidants; Central nervous system stimulants; Diagnosis; Estrogens; Genetics; Nerve growth factor

Indexed keywords

ACETYLCHOLINE; ALUMINUM; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ANTIOXIDANT; APOLIPOPROTEIN E; CHOLINESTERASE INHIBITOR; CYCLOSERINE; ESTROGEN; GLUTAMATE RECEPTOR AGONIST; INDOMETACIN; MUSCARINIC AGENT; NERVE GROWTH FACTOR; NEUROTROPHIN; NICOTINIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE C; SEROTONIN 1A ANTAGONIST; TACRINE; TAU PROTEIN; VELNACRINE; ZINC;

ALZHEIMER DISEASE; CHOLINERGIC SYSTEM; CHROMOSOME 21; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; HUMAN; NEUROFIBRILLARY TANGLE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PSYCHOLOGIC TEST; REVIEW; SENILE PLAQUE;

EID: 0029951158     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/53.13.1545     Document Type: Review

References (122)

1. Beck JC, Benson DF, Scheibel AB et al. Dementia in the elderly: the silent epidemic. Ann Intern Med. 1982; 97:231-41.
2. Larson EB, Burton VR, Featherstone HJ et al. Dementia in elderly outpatients: a prospective study. Ann Intern Med. 1984; 100:417-23.
3. Harrison's principles of internal medicine. 12th ed. Wilson JD, ed. New York: McGraw-Hill; 1991.
4. Pfeffer RI, Afifi AA, Chance JM. Prevalence of Alzheimer's disease in a retirement community. Am J Epidemiol. 1987; 125:420-36.
5. Evans DA, Funkenstein HH, Albert MS et al. Prevalence of Alzheimer's disease in a community population of older persons. JAMA. 1989; 262:2551-6.
6. Alberts B, Bray D, Lewis J et al. Molecular biology of the cell. New York: Garland; 1994.
7. Becker JT, Boller F, Lopez OL et al. The natural history of Alzheimer's disease: description of cohort and accuracy of diagnosis. Arch Neurol. 1994; 51:585-94.
8. Koss E. Neuropsychology and Alzheimer's disease. Clin Geriatr Med. 1994; 10:299-313.
9. Jobst KA, Smith AD, Szatmari M et al. Detection in life of confirmed Alzheimer's disease using a simple measurement of medial temporal lobe atrophy by computerized tomography. Lancet. 1992; 340:1179-83.
10. Jobst KA, Smith AD, Szatmari M et al. Rapidly progressing atrophy of medial temporal lobe in Alzheimer's disease. Lancet. 1994; 343:829-30.
11. McKhann G, Drachman D, Holstein M et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34:939-44.
12. Folstein M, Folstein S, McHugh PR et al. Mini-Mental State: a practical method for grading the cognitive state of patients for clinicians. J Psychiatr Res. 1975; 12:189-98.
13. Welsh K, Butters N, Hughes J et al. Detection of abnormal memory declines in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol. 1991; 48:278-81.
14. Yamaguchi H, Nakazato Y, Hirai S et al. Immunoelectron microscopic localization of amyloid-β protein in the diffuse plaques of Alzheimer-type dementia. Brain Res. 1990; 508:320-4.
15. Delaère P, He Y, Fayet G et al. βA4 deposits are constant in the brain of the oldest old: an immunocytochemical study of 20 French centenarians. Neurobiol Aging. 1993; 14:191-4.
16. Glenner GG, Wong CW. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem Biophys Res Commun. 1984; 122:1131-5.
17. Gandy S, Greengard P. Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities. Trends Pharmacol Sci. 1992; 13:108-13.
18. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci. 1991; 12:383-8.
19. 717) mutants. Science. 1994; 264: 1336-40.
20. Games D, Adams D, Alessandrini R et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature. 1995; 373:523-7.
21. Cai X-D, Golde TE, Younkin SG. Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science. 1993; 259:514-6.
22. Pike CJ, Walencewicz AJ, Glabe CG et al. Aggregation-related toxicity of synthetic β-amyloid protein in hippocampal cultures. Eur J Pharmacol. 1991; 207:367-8.
23. Loo DT, Copani A, Pike CJ et al. Apoptosis is induced by β-amyloid in cultured central nervous system neurons. Proc Natl Acad Sci U S A. 1993; 90:7951-5.
24. Mattson MP, Cheng B, Davis D et al. β-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci. 1992; 12:376-89.
25. Terry RD, Masliah E, Salmon DP et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol. 1991; 30:572-80.
26. Lorenzo A, Yankner BA. β-Amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc Natl Acad Sci U S A. 1994; 91:12243-7.
27. Cummings BJ, Cotman CW. Image-analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet. 1995; 346:1524-8.
28. Hilbich C, Kisters-Woike B, Reed J et al. Aggregation and secondary structure of synthetic amyloid βA4 peptides of Alzheimer's disease. J Mol Biol. 1991; 218:149-63.
29. Wisniewski T, Ghiso J, Frangione B. Alzheimer's disease and soluble Aβ. Neurobiol Aging. 1994; 15:143-52.
30. Ashall F, Goate AM. Role of the β-amyloid precursor protein in Alzheimer's disease. Trends Biochem. 1994; 19:42-5.
31. Selkoe DJ. Physiological production of the β-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci. 1993; 16:403-8.
32. Esch FS, Keim PS, Beattie EC et al. Cleavage of amyloid-β peptide during constitutive processing of its precursor. Science. 1990; 248:1122-4.
33. Hooper NM, Turner AJ. Specificity of the Alzheimer's amyloid precursor protein α-secretase. Trends Biochem. 1995; 20:15-6.
34. Haass C, Koo EH, Mellon A et al. Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments. Nature. 1992; 357: 500-2.
35. Caporaso G, Gandy SE, Buxbaum JD et al. Chloroquine inhibits intracellular degradation but not secretion of Alzheimer β/A4 amyloid precursor protein. Proc Natl Acad Sci U S A. 1992; 89:2252-6.
36. Seubert P, Oltersdorf T, Lee MG et al. Secretion of β-amyloid precursor protein cleaved at the amino terminus of the β-amyloid peptide. Nature. 1993; 361:260-3.
37. Seubert P, Vigo-Pelfrey C, Esch F et al. Isolation and quantification of soluble Alzheimer's β-peptide from biological fluids. Nature. 1992; 359:325-7.
38. Buxbaum JD, Koo EH, Greengard P. Protein phosphorylation inhibits production of Alzheimer amyloidβ/A4 peptide. Proc Natl Acad Sci U S A. 1993; 90:9195-8.
39. Buxbaum JD, Oishi M, Chen HI et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid precursor protein. Proc Natl Acad Sci U S A. 1992; 89:10075-8.
40. Nitsch RM, Slack BE, Wurtman RJ et al. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science. 1992; 258:304-7.
41. Buxbaum JD, Ruefli AA, Parker CA et al. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci US A. 1994; 91:4489-93.
42. Jaffe AB, Toran-Allerand CD, Greengard P et al. Estrogen regulates metabolism of Alzheimer amyloid β precursor protein. J Biol Chem. 1994; 269:13065-8.
43. Sherrington R, Rogaev EI, Liang Y et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature. 1995; 375:754-60.
44. Levy-Lahad E, Wasco W, Poorkaj P et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science. 1995; 269:973-7.
45. Naidu A, Quon D, Cordell B. β-Amyloid peptide produced in vitro is degraded by proteinases released by cultured cells. J Biol Chem. 1995; 270:1369-74.
46. Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer's disease. Trends Neurosci. 1993; 16:460-5.
47. Koski KS. The molecular and cellular biology of tau. Brain Pathol. 1993; 3:39-43.
48. Goedert M, Jakes R, Crowther RA et al. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc Natl Acad Sci U S A. 1993; 90:5066-70.
49. Greenberg SM, Koo EH, Selkoe DJ et al. Secreted β-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc Natl Acad Sci U S A. 1994; 91:7104-8.
50. Matsuo ES, Shin R-W, Billingsley ML et al. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron. 1994; 13:989-1002.
51. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988; 240:622-9.
52. Nambia Y, Tomonaga M, Kawasaki H et al. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991; 541:163-6.
53. Strittmatter WJ, Saunders AM, Schmechel D et al. Apolipo-protein E: high-avidity binding to β-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90:1977-81.
54. Pericak-Vance MA, Bebout JL, Gaskell PC Jr et al. Linkage studies in familial Alzheimer disease: evidence for chromosome 19 linkage. Am J Hum Genet. 1991; 48:1034-50.
55. Rall SC, Mahley RW. The role of apolipoprotein E genetic variants in lipoprotein disorders. J Intern Med. 1992; 231:653-9.
56. Poirer J, Davignon J, Bouthillier D et al. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 1993; 342:697-9.
57. Noguchi S, Murakami K, Yamada N. Apolipoprotein E geno-type and Alzheimer's disease. Lancet. 1993; 342:737. Letter.
58. Payami H, Kaye J, Heston LL et al. Apolipoprotein E geno-type and Alzheimer's disease. Lancet. 1993; 342:738. Letter.
59. Polvikoski T, Sulkava R, Haltia M et al. Apolipoprotein E, dementia, and cortical deposition of β-amyloid protein. N Engl J Med. 1995; 333:1242-7.
60. Corder EH, Saunders AM, Strittmatter WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261:921-3.
61. Hardy J, Crook R, Prihar G et al. Senile dementia of the Lewy body type has an apolipoprotein E/ε4 allele frequency intermediate between controls and Alzheimer's disease. Neurosci Lett. 1994; 182:1-2.
62. Hardy J, Crook R, Perry R et al. ApoE genotype and Down's syndrome. Lancet. 1994; 343:979-80.
63. Ignatius MJ, Gebicke-Harter PJ, Skene JHP et al. Expression of apolipoprotein E during nerve degeneration and regeneration. Proc Natl Acad Sci U S A. 1986; 83:1125-9.
64. Poirer J. Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci. 1994; 17:525-30.
65. Strittmatter WJ, Weisgraber KH, Huang DY et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci U S A. 1993; 90:8098-102.
66. Schmechel DE, Saunders AM, Strittmatter WJ et al. Increased amyloid β peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer's disease. Proc Natl Acad Sci U S A. 1993; 90:9649-53.
67. Strittmatter WJ, Saunders AM, Goedert M et al. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer's disease. Proc Natl Acad Sci U S A. 1994; 91:11183-6.
68. Huang DY, Goedert M, Jakes R et al. Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease. Neurosci Lett. 1994; 182:55-8.
69. Han S-H, Hulette C, Saunders AM et al. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls. Exp Neurol. 1994; 128:13-26.
70. Strittmatter WJ, Weisgraber KH, Goedert M et al. Hypothesis: microtuble instability and paired helical filament formation in the Alzheimer disease are related to apolipoprotein E genotype. Exp Neurol. 1994; 125:163-71.
71. Nathan BP, Bellosta S, Sanan DA et al. Differential effects of apolipoprotein E3 and E4 on neuronal growth in vitro. Science. 1994; 264:850-2.
72. Farrer LA, Brin MF, Elsas L et al. Statement on the use of apolipoprotein E testing for Alzheimer's disease. JAMA. 1995; 274:1627-9.
73. Small GW, Mazziotta JC, Collins MT et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA. 1995; 273:942-7.
74. Cooper JR, Bloom FE, Roth RH. The biochemical basis of neuropbarmacology. 6th ed. New York: Oxford Univ. Press; 1991.
75. Hall ZW. An introduction to molecular neurobiology. Sunderland, MA: Sinauer; 1992.
76. Molchan SE, Martinez RA, Hill JL et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Rev. 1992; 17:215-26.
77. Robbins SL, Angell M, Kumar V. Basic pathology. 3rd ed. Philadelphia: Saunders; 1981.
78. Scinto LFM, Daffner KR, Dressier D et al. A potential noninvasive neurobiological test for Alzheimer's disease. Science. 1994; 266:1051-4.
79. Marx JL, Kumar SR, Thach AB et al. Detecting Alzheimer disease. Science. 1995; 267:1577. Letter.
80. Davis KL, Thal LJ, Gamzu ER et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. N Engl J Med. 1992; 327:1253-9.
81. Knapp MJ, Knopman DS, Solomon PR et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA. 1994; 271:985-91.
82. Antuono PG. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. Arch Intern Med. 1995; 155:1766-72.
83. Clipp EC, Moore MJ. Caregiver time use. An outcome measure in clinical trial research on Alzheimer's disease. Clin Pharmacol Ther. 1995; 58:228-36.
84. Parnetti L. Clinical pharmacokinetics of drugs for Alzheimer's disease. Clin Pharmacokinet. 1995; 29:110-29.
85. Brufani M, Marta M, Pomponi M. Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia. Eur J Biochem. 1986; 157:115-20.
86. Flynn DD, Ferrari-DiLeo G, Mash DC et al. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem. 1995; 64:1888-91.
87. Lefkowitz RJ, Hoffman BB, Taylor P. Neurotransmission: the autonomic and somatic motor nervous systems. In: Goodman and Gilman's the pharmacological basis of therapeutics. 9th ed. Hardiman JG, Limbird LE, Molinoff PB et al., eds. New York: McGraw-Hill; 1996:117-9.
88. Brenner DE, Kukull WA, van Belle G et al. Relationship between cigarette smoking and Alzheimer's disease in a population-based case-control study. Neurology. 1993; 43:293-300.
89. The Canadian Study of Health and Aging. Risk factors for Alzheimer's disease in Canada. Neurology. 1994; 44:2073-80.
90. Riggs JE. Smoking and Alzheimer's disease: protective effect or differential survival bias? Lancet. 1993; 342:793-4. Letter.
91. Hardy J, Roberts GW. Smoking and neurodegenerative diseases. Lancet. 1993; 342:1238. Letter.
92. Larrick JW, Wright SC. Smoking and neurodegenerative diseases. Lancet. 1993; 342:1238. Letter.
93. Morens DM, Grandinetti A, Reed D et al. Smoking associated protection from Alzheimer's and Parkinson's disease. Lancet. 1994; 343:356-7. Letter.
94. Van Duijn CM, Havekes LM, Van Broeckhoven C et al. Apolipoprotein E genotype and association between smoking and early onset Alzheimer's disease. BMJ. 1995; 310:627-31.
95. Maelicke A, Albuquerque EX. New approach to drug therapy in Alzheimer's dementia. Drug Discov Today. 1996; 1:53-9.
96. Wurtman RJ. Choline metabolism as a basis for the selective vulnerability of cholinergic neurons. Trends Neurosci. 1992; 15:117-22.
97. + depolarization on choline kinase and choline acetyltransferase activities in superior cervical sympathetic ganglia excised from rats. J Neurochem. 1987; 48:1448-53.
98. Ulus IH, Wurtman RJ, Mauron C et al. Choline increases acetylcholine release and protects against the stimulation-induced decrease in phosphatide levels within membranes of the rat corpus striatum. Brain Res. 1989; 484:217-27.
99. Barker PA, Murphy RA. The nerve growth factor receptor: a multicomponent system that mediates the actions of the neurotrophin family of proteins. Mol Cell Biochem. 1992; 110:1-15.
100. Barker PA, Shooter EM. Disruption of NGF binding to the low affinity neurotrophin receptor p75 LNTR reduces NGF binding to trkA on PC12 cells. Neuron. 1994; 13:203-15.
101. Meakin SO, Shooter EM. The nerve growth factor family of receptors. Trends Neurosci. 1992; 15:323-31.
102. Lindsay RM, Wiegand SJ, Altar CA et al. Neurotrophic factors: from molecule to man. Trends Neurosci. 1994; 17:182-90.
103. Cheng B, Mattson MP. NGF and bFGF protect rat hippocampal and human cortical neurons against hypoglycemic damage by stabilizing calcium homeostasis. Neuron. 1991; 7: 1031-41.
104. Cheng B, Mattson MP. NT-3 and BDNF protect CNS neurons against metabolic/excitotoxic insults. Brain Res. 1994; 640: 56-67.
105. Rylett RJ, Williams LR. Role of neurotrophins in cholinergic-neurone function in the adult and aged CNS. Trends Neurosci. 1994; 17:486-9.
106. Greenamyre JT, Maragos WF. Neurotransmitter receptors in Alzheimer's disease. Cerebrovasc Brain Metab Rev. 1993; 5:61-94.
107. Collinridge GL. Long term potentiation in the hippocampus: mechanisms of initiation and modulation by neurotransmitter. Trends Pharmacol Sci. 1985; 6:407-11.
108. Francis PT, Sims NR, Procter AW et al. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem. 1993; 60:1589-604.
109. 1A receptor antagonists: utility as research tools and therapeutic agents. Trends Pharmacol Sci. 1993; 14:441-8.
110. Olanow CW. A radical hypothesis for neurodegeneration. Trends Neurosci. 1993; 16:439-44.
111. Shigenaga MK, Hagen TM, Ames BN. Oxidative damage and mitochondrial decay in aging. Proc Natl Acad Sci U S A. 1994; 91:10771-8.
112. Schubert D, Behl C, Lesley R et al. Amyloid peptides are toxic via a common oxidative mechanism. Proc Natl Acad Sci U S A. 1995; 92:1989-93.
113. Multhaup G, Schlicksupp A, Hesse L et al. The amyloid precursor protein of Alzheimer's disease in the reduction of copper(II) to copper(I). Science. 1996; 271:1406-9.
114. McMillan MK, Thai L, Hong J-S et al. Brain injury in a dish: a model for reactive gliosis. Trends Neurosci. 1994; 17:138-42.
115. Meda L, Cassatella MA, Szendrei GI et al. Activation of microglial cells by β-amyloid and interferon-γ. Nature. 1995; 374:647-50.
116. Eikelenboom P, Zhan SS, van Gool WA et al. Inflammatory mechanisms in Alzheimer's disease. Trends Pharmacol Sci. 1994; 15:447-50.
117. Schnabel J. New Alzheimer's therapy suggested. Science. 1993; 260:1719-20. News.
118. Paganini-Hill A, Henderson VW. Estrogen deficiency and risk of Alzheimer's disease in women. Am J Epidemiol. 1994; 140:256-61.
119. Henderson VW, Paganini-Hill A. Estrogen replacement therapy in older women. Arch Neurol. 1994; 51:896-900.
120. Fasman GD, Moore CD. The solubilization of model Alzheimer tangles: reversing the β-pleated sheet conformation induced by aluminum with silicates. Proc Natl Acad Sci U S A. 1994; 91:11232-5.
121. Bush AI, Pettingell WH, Multhaup G et al. Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science. 1994; 265:1464-7.
122. Crapper-McLachlan DR, Dalton AJ, Kruck TP et al. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991; 337:1304-8.